Trastuzumab and hyaluronidase combination is indicated for the treatment of breast cancer.
Trastuzumab along with hyaluronidase is indicated for the treatment of breast cancer among adults.
3. Allergy to Trastuzumab
Trastuzumab is available as injection: In a single vial of injection, 600 mg trastuzumab and 10,000 units hyaluronidase is available.
It is administered subcutaneously (into the fatty layer under the skin) for over 2-5 minutes once every three weeks.
In patients with adjuvant breast cancer, Trastuzumab can be given for 52 weeks or until disease recurrence, whichever occurs first. Extending the treatment beyond one year is not recommended.
In case a dose is missed, the next dose should be given as soon as possible and the interval between doses should not be less than 3 weeks.
General: Fatigue, Injection site reaction, headache, fever, chills, infection
Musculoskeletal: Joint pain, muscle pain
Respiratory: Upper respiratory tract infection, cough
Nervous system: Insomnia (lack of sleep)
The drug can cause heart failure. Monitor cardiac function before and during treatment.
The drug can cause pulmonary toxicity in the form of anaphylaxis (allergic reaction), angioedema (swelling under the skin), and acute respiratory distress syndrome (accumulation of fluid in lungs, symptom- shortness of breath).
If taken during pregnancy, Trastuzumab can cause oligohydramnios (volume of amniotic fluid is low), and neonatal death. Effective contraception must be used during treatment and 7 months after the last dose is given.
Trastuzumab can exacerbate chemotherapy-induced low white cell count.
Monitor patients for reactions like skin rash, shortness of breath, nausea, dizziness, low blood pressure.
Trastuzumab can interact with
Store Trastuzumab in the refrigerator at 2 to 8 o C. Do not shake or freeze.